Editorial: Somatostatin analogs for graves' ophthalmopathy - Do they bounce off like a rubber bullet?

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 12, 2004, Pages 5908-5909

  Bartalena, Luigi ^a   Marcocci, Claudio ^b   Pinchera, Aldo ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTIOXIDANT; CYCLOSPORIN; GLUCOCORTICOID; PASIREOTIDE; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG; DRUG DERIVATIVE; OCTREOTIDE; SOMATOSTATIN;

BINDING AFFINITY; CLINICAL TRIAL; DECOMPRESSION; DIPLOPIA; DRUG EFFECT; DRUG RECEPTOR BINDING; EDITORIAL; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; TREATMENT FAILURE; DELAYED RELEASE FORMULATION; GRAVES DISEASE; NOTE;

DELAYED-ACTION PREPARATIONS; GRAVES DISEASE; HUMANS; OCTREOTIDE; SOMATOSTATIN;

EID: 16644382738     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1981     Document Type: Editorial

References (12)

1. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21:168-199
2. Wieisinga WM, Prummel MF, Tenwee CB 2004 Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 27:259-264
3. Bartalena L, Marcocci C, Pinchera A 2002 Graves' ophthalmopathy: a preventable disease? Eur J Endocrinol 146:457-461
4. Krassas GE 2004 Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 27:281-287
5. Bartalena L, Tanda ML, Piantanida E, Lai A 2003 The role of somatostatin analogs in the management of Graves' ophthalmopathy. J Endocrinol Invest 26(8 Suppl):109-113
6. Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA 2000 Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 25:63-71
7. Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA 2002 Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab 87:5125-5129
8. Dickinson JA, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P 2004 Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89:5910-5915
9. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A 1998 Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 129:632-635
10. Caron PJ, Rohmer V, Orgiazzi J, Nocaudie M, Beckers A, Bourdeix I, Dejager S, Wemeau J 2004 Three-month octreotide-LAR treatment in patients with Graves orbitopathy: clinical results of a randomized, placebo-controlled, double-blind study. Turk J Endocrinol Metab 8(1 Suppl):29 (Abstract)
11. Saveanu A, Gunz G, Dufour H, Enjalbert A, Culler MD, Jaquet P 2003 Distribution and functionality of the somatostatin receptor subtypes in acromegaly. J Endocrinol Invest 26(8 Suppl):4-7
12. Boerlin V, van der Hoek J, Beglinger Ch, Poon KW, Hartmann S, Dutreix C, Kovarik JM, Bruns Ch, Weckbecker G, Lewis I, Schnieper P, Hofland J, Lamberts SWJ 2003 New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 26(8 Suppl):14-16